Protagonist Therapeutics, Inc
PTGXProtagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for various diseases. Founded with the aim of harnessing the potential of peptides as targeted and effective treatments, the company primarily advances programs in gastrointestinal and inflammatory diseases, leveraging proprietary peptide delivery platforms.
Company News
The polycythemia vera market is expected to expand significantly by 2036, growing at 8.9% CAGR from a 2025 valuation of approximately USD 2 billion. Nine major pharmaceutical companies are advancing next-generation therapies in various clinical development stages, with rusfertide from Protagonist Therapeutics and Takeda expected to be the first n...
Johnson & Johnson demonstrates resilience during market downturns, with shares falling less than 2% while the S&P 500 dropped over 7%. The healthcare giant maintains strong fundamentals including 63 consecutive years of dividend increases, $94.2 billion in 2025 revenue (up 6%), and 51 drug approvals last year. However, the stock faces headwinds f...
The FDA approved Icotyde (icotrokinra), an oral IL-23 receptor antagonist for moderate-to-severe plaque psoriasis developed by Johnson & Johnson and Protagonist Therapeutics. The approval triggers a $50 million milestone payment to Protagonist with potential for up to $580 million in additional payments. AbbVie's stock fell 5.20% as analysts view...
Hedge fund BVF fully exited its position in Protagonist Therapeutics (PTGX), selling 2.56 million shares worth $170.12 million. Despite the stock rallying 120% over the past year, the fund's exit reflects a disciplined capital rotation strategy following the company's New Drug Application submission for rusfertide in polycythemia vera, marking a ...
